1. Neuropsychiatric involvement in pediatric systemic lupus erythematosus.
- Author
-
Benseler, S. M. and Silverman, E. D.
- Subjects
- *
PEDIATRIC neuropsychiatry , *NEUROPSYCHIATRY , *BIOLOGICAL psychiatry , *SYSTEMIC lupus erythematosus , *AUTOIMMUNE diseases , *PSYCHOSES - Abstract
Neuropsychiatric (NP) manifestations are found in approximately 25% of children and adolescents with pediatric SLE (pSLE). In 70% of those, NP involvement will occur within the first year from the time of diagnosis. Headaches (66%), psychosis (36%), cognitive dysfunction (27%) and cerebrovascular disease (24%) are the most common presentations. The support of a psychiatrist is often required. Anti-phospholipid antibodies are associated with distinct NP disease entities and may be implicated in the pathogenesis of several manifestations of NP-pSLE including chorea, cerebrovascular disease and seizures. The role of novel auto-antibodies and imaging modalities is currently explored. The treatment of NP-pSLE is not based on prospective studies; however, an immunosuppressive combination therapy consisting of high doses of prednisone and a second line agent such as cyclophosphamide or azathioprine is commonly suggested for children with NP-pSLE. The role of novel therapies is currently studied. The outcome of children with NP-pSLE is relatively good. The overall survival is 95–97%, 20% of children experience a disease flare during childhood and 25% have evidence of permanent neuropsychiatric damage. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF